Introduction {#S1}
============

The sense of smell makes an important and often underestimated contribution to our quality of life. New evidence is increasingly debunking the old myth that in humans the sense of smell is scarcely sensitive and of limited use ([@B105]). Many of our daily actions are driven by olfaction (i.e., olfactory-driven food choice, detection of spoiled food before it enters the mouth).

The olfactory system has remarkable features unique among sensory systems in particular and the nervous system in general. It is the only sensory organ that has its primary neurons in direct contact with the external world: the olfactory receptor neurons (ORNs) in the nasal cavity. Olfactory receptor neurons are bipolar neurons that, throughout the life span of an animal, degenerate and are replaced by new neurons originating from a pool of stem cells in the basal part of the olfactory epithelium (OE; [@B84]; [@B16]; [@B146]). Neuronal regeneration is a distinctive feature of the OE: few areas of the nervous system are known to have regenerative ability.

To detect odorants, ORNs express the largest family of G protein--coupled receptors (GPCRs) so far discovered: the odorant receptors (ORs). Interestingly, ORs have increasingly been described in several other organs ([@B49]; [@B104]). In the OE, these receptor proteins can bind and be activated by different odorant molecules with different chemophysical features and trigger a signal transduction cascade that ultimately leads to electrical signals (action potentials) traveling to the olfactory bulb (OB; reviewed in [@B106]; [@B138]; [@B128]). Thus, as an island of neurons in the sea of the external world, the OE is an outpost that can potentially inform our knowledge about the brain's physiological and pathological status.

In neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD), olfactory dysfunction appears relatively early compared to other symptoms ([@B45], [@B46]; [@B69]). In idiopathic PD, olfactory loss can occur several years prior to the onset of the motor symptoms ([@B46]). Indeed, olfactory dysfunction has been designated as one of the diagnostic criteria for PD since 2006 ([@B157]).

Our understanding of the olfactory pathophysiology for AD is less clear than that for PD, and it is still unclear which neural substrates are responsible for AD ([@B47]). In this review, we summarize studies on the involvement of the olfactory system in AD, with a focus on events during the early stages of olfactory processing, in the OE and OB. We first outline the development and function of the OE and OB, followed by an overview of the hypotheses of AD development and pathology, before discussing the interrelation of AD with the olfactory system. Several studies (reviewed in [@B116]) support the notion that olfactory dysfunction develops before cognitive decline and prior to signs of dementia in patients with AD, in those with a genetic risk of AD, and with amnesic mild cognitive impairment. Thus, changes in the early stages of olfaction have the potential to be an inexpensive and non-invasive diagnostic tool and biomarker. Currently, the use of olfactory function as the sole predictor of the AD is limited ([@B163]).

The Olfactory System {#S2}
====================

The Olfactory Epithelium {#S2.SS1}
------------------------

Two main neuronal cell populations are present in the OE: immature and mature ORNs. Olfactory receptor neurons are bipolar neurons with a cell body located in the middle part of the OE and a dendrite that extends toward the nasal cavity, ending with a knob bearing several cilia. At the other end of the cell body, an axon exits the OE from the basal lamina and reaches the OB in the brain ([Figure 1](#F1){ref-type="fig"}). Mature ORNs can be identified because of their higher expression of olfactory marker protein, a cytosolic protein involved in the odorant response ([@B20]; [@B72]; [@B137]; [@B94]; [@B43]) and widely used as a molecular marker or driver for the expression of genes in mature neurons. Mature ORNs express all the proteins to elicit the odorant response, including the ORs (reviewed in [@B83]), which are GPCRs expressed in ORN cilia. Odorant receptors represent by far the most numerous class of genes in vertebrate genomes, representing on average 3--5% of all genes across species, and were first elegantly cloned from the rat OE in 1991 by Linda Buck and Richard Axel ([@B8]). Different ORs bind different odorant molecules with many different chemical features, and they can be either broadly tuned or narrowly selective.

![Organization of the olfactory system. The pseudostratified olfactory epithelium (OE) consists of sustentacular (Sus) cells, olfactory receptor neurons (ORNs), and basal cells. The Sus cells have a columnar cell body, with an apical membrane with microvilli. Two main populations of neurons are present: mature and immature ORNs. Both ORN types are bipolar neurons with dendritic processes projecting toward the apical surface of the epithelium. In mature ORNs, several cilia protrude from the dendritic knob. Horizontal basal cells (HBCs) and globose basal cells (GBCs) constitute the stem cells of the OE. They are able to replace the different cell types on a daily basis or in case of injury. Axons from ORNs expressing the same odorant receptor type (represented by ORNs of the same color) converge in the olfactory bulb (OB) in round structures dense with synapses, called glomeruli. The second-order neurons (mitral/tufted cells) have a single dendrite projecting to a single glomerulus and lateral dendrites that contact dendrites of granule cells.](fnins-14-00440-g001){#F1}

Odorant signal transduction takes place in the olfactory cilia. It starts with the binding of an odorant molecule to an OR, which triggers a series of molecular events mediated by the second messenger cyclic adenosine monophosphate (cAMP), generated by adenylyl cyclase type 3 (AC3). The odorant-induced increase in ciliary cAMP generates a transduction current carried by Na^+^ and Ca^2+^ via entry through the cyclic nucleotide-gated channels first, followed by Cl^--^ exit through Ca^2+^-activated Cl^--^ channels (TMEM16B or anoctamin-2; reviewed in [@B127]; [@B83]; [@B128]; [@B42]). The ensuing depolarization generates action potentials that are then sent to the OB.

The OE contains cell types other than the functional units of the olfactory system, the ORNs ([Figure 1](#F1){ref-type="fig"}; [@B2]; [@B59]; [@B149]):

1.  Microvillar sustentacular or supporting cells ([@B122]; [@B149]);

2.  Microvillar cells, a relatively small heterogeneous population in terms of phenotype and function ([@B114]; [@B111]; [@B6]; [@B110]; [@B66]; [@B76]; [@B87]); and

3.  At least two populations of basal cells that constitute the stem cell niche of the OE: horizontal or dark basal cells (HBCs) and globose basal cells (GBCs; [Figure 1](#F1){ref-type="fig"}; [@B59]; [@B68]; [@B146]).

Microvillar sustentacular cells are goblet-shaped cells with a basal end foot that contacts the OE basal lamina and microvilli located at their apical side. They are thought to play a range of roles, from detoxification of the OE to odorant transformation ([@B139]; [@B161]). They produce neurotrophic and neuromodulator molecules such as endocannabinoids, insulin, and ATP ([@B38]; [@B17]; [@B65]; [@B67]). Interestingly, several studies have shown that ATP is involved in neuroprotection and neuroproliferation ([@B64]; [@B77]; [@B76]).

Both types of basal cell populations are multipotent, but HBCs are considered reserve stem cells, whereas GBCs are responsible for continuous replacement of ORNs and other cell types in the OE. Horizontal basal cells are usually dormant in the OE, but severe OE lesions or toxin-mediated injury wakes up this stem cell population, which gives rise to a plethora of cell types, including ORNs and sustentacular cells (reviewed in [@B146]). Globose basal cells are round-shaped cells with a relatively small cytoplasm, located in clusters separated by gaps. Among the heterogeneous population of GBCs are those that will give rise to the mature ORNs ([@B59]; [@B146]).

The Olfactory Bulb {#S2.SS2}
------------------

The OB is the first relay station of the olfactory system in the brain ([Figure 1](#F1){ref-type="fig"}). Olfactory receptor neurons expressing the same OR type convey their axon to neuropil-like structures in the OB called glomeruli. Thus, the OB is topographically organized, with each glomerulus representing a single type of OR. Glomeruli are surrounded by periglomerular cells (PGCs) and are rather uniform in size (approximately 50-μm diameter in mice). In the glomeruli, ORN axons connect to the apical dendrite of mitral/tufted cells, whose cell bodies are located in the external and internal plexiform layers, where GABAergic granule cells (GCs) also reside ([Figure 1](#F1){ref-type="fig"}). Olfactory receptor neurons also make synapses onto several populations of PGCs.

The mechanisms by which ORN axons reach the correct glomerulus in the OB and form the glomerular structure are not fully understood. During early development and map formation, axons project to stereotypical areas along the dorsoventral and anteroposterior axes in the OB. Molecules such as neuropilins, ephrin As, and semaphorins act as guidance cues expressed by ORN axons ([@B35]; [@B70]; [@B158]). The mechanism involved in the map formation along the anteroposterior and dorsoventral axes seems to be mainly cAMP dependent at first. Recently, [@B167] showed that a population of immature ORNs can act as "navigators," mediating the initial coalescing of axons into protoglomeruli in the OB.

In addition, other guidance molecules, whose expression seems OR dependent, play important roles in allowing axons expressing the same OR to target the same glomerulus ([@B80]; [@B118]; [@B159]). Ligand-dependent activity seems to regulate the expression of guidance cues that drive axon coalescence and glomerular refinement ([@B97]; [@B159]; [@B169]). Odorant receptors may also mediate axon targeting directly by binding small peptides ([@B170]). The formation of the correct glomerular map is considered important for odor coding; alteration in the map could lead to deficits in odor coding and, ultimately, in olfactory-driven behaviors.

Pathophysiological Mechanisms of Alzheimer's Disease {#S3}
====================================================

Alzheimer's disease is a devastating neurodegenerative disorder that affects 47 million people globally ([@B40]). As yet no cure for AD exists, and as AD progresses, memory loss and cognitive disorder present debilitating problems for patients and increased burden for caregivers.

Alzheimer's disease is characterized by a long, insidious progression, with a preclinical phase that can last from 5 to 15 years before the onset of disease symptoms, which then worsen in the symptomatic phase that lasts up to 10 years ([@B98]). It is important to understand how the disease progresses and whether it is possible to identify any biomarker in the very early stage of the disease prior to the manifestation of cognitive symptoms.

Amyloid and Tau Cascade {#S3.SS1}
-----------------------

Alzheimer's disease has two specific neuropathological markers: first, extracellular deposition of amyloid-β (Aβ) protein as diffuse and neuritic plaques and, second, dystrophic neurites and intraneuronal neurofibrillary tangles (NFTs) composed of aggregated hyperphosphorylated tau protein ([@B73]). In the earliest working hypothesis of AD pathogenesis, known as the amyloid cascade hypothesis ([@B62]), the initial step of the disease is the deposition of Aβ, followed by subsequent tau deposition, neurodegeneration, and ultimately cognitive decline. This amyloid hypothesis has recently been extended to include inflammatory mechanisms (described in *ApoE and the Inflammatory Hypothesis*).

The initial deposition of Aβ begins with a series of secretase enzymes (MMP24, ADAM10, BACE1, PSEN1, and PSEN2) that cleave the membrane protein APP (amyloid precursor protein), in sequence and at different sites; some of the resulting products are Aβ~40~ and Aβ~42~ ([Figure 2](#F2){ref-type="fig"}). The proteolytic function of BACE1 and γ-secretase seems to be mainly in the intracellular endosomes; the combined action of the complexes of these two secretases forms Aβ from APP. The polypeptides Aβ~40~ and Aβ~42~ have a tendency to aggregate to form higher-order oligomers with a wide molecular weight range, which eventually leads to the formation of fibrils ([@B145]). The importance of Aβ aggregation in triggering the AD cascade is backed by genetic data, although Aβ seems to be necessary but not sufficient ([@B98]).

![Main pathways involved in Alzheimer's disease pathophysiology. Amyloid-β 40/42 (Aβ~40/42~) is produced by the sequential cleavage of amyloid precursor protein (APP) by BACE1 (β-secretase 1) and γ-secretase complex in the endosome. After secretion into the interstitial fluid, Aβ~40/42~ forms oligomers and Aβ fibrils that contribute in different ways to Alzheimer's disease pathology. In particular, Aβ fibrils activate the hyperphosphorylation of tau, promoting its oligomerization and the formation of intracellular neurofibrillary tangles, leading to synaptotoxicity and neurodegeneration. Amyloid-β fibrils also activate microglia by apolipoprotein E (ApoE)--dependent mechanisms. Microglia activation can have both beneficial and damaging effects: microglia reduce and delay Aβ fibril formation, but the prolonged release of inflammatory mediators could lead to neurodegeneration. Finally, ApoE lipoprotein also modulates Aβ oligomerization and Aβ fibrils. CTF, C-terminal fragment; sAPPβ, soluble APP β; C99, the 99-amino acid C-terminal domain of APP.](fnins-14-00440-g002){#F2}

None of the Aβ peptides is intrinsically toxic; rather, a change in their ratio, favoring the more insoluble form, is linked to AD. For example, Aβ~40~ formation is altered when PSEN1 is mutated, thus favoring an increased Aβ~42~/Aβ~40~ ratio ([@B79]). Minor changes in the ratio can drive the seeding of plaques and, via an independent mechanism, neurotoxicity. In other words, a mixture of various oligomers and aggregates (an "Aβ cocktail") and not one specific toxic oligomer exists to interact with cellular membranes and proteins in non-specific ways ([@B13]).

A driver of neurodegeneration in AD is the tau protein in its aggregated and hyperphosphorylated forms ([Figure 2](#F2){ref-type="fig"}). There might be a link between Aβ deposition and tau protein homeostasis, such that elevated Aβ formation is sufficient to drive tau pathology. Tau protein is encoded by the *MAPT* (microtubule-associated protein tau) gene and is primarily expressed by neurons in the brain. It is alternatively spliced at the N-terminal domain (N) and microtubule-binding repeat domain (R), which yields six distinct isoforms: 0N3R, 0N4R, 1N3R, 1N4R, 2N3R, and 2N4R. How tau functions in the central nervous system is not fully elucidated. It seems to be involved in microtubule assembly, stabilization of neuronal axons, and regulation of microtubule-associated transport ([@B164]; [@B44]).

In several cases, because of the many different phosphorylation sites of the tau protein, unusual phosphorylation causes a decrease in binding affinity for microtubules ([@B14]; [@B102]). Tau then cannot bind correctly to the microtubular structure, resulting in an increase of the cytosolic pool that can promote aggregation and fibrillization. Relocation of hyperphosphorylated tau from the axonal to other cellular compartments, like dendrites and the soma, can then lead to decline of synaptic function ([@B15]). It seems that tau is mainly degraded in the cell body and continues to accumulate in the axon, which lacks degrading enzymes. This scenario makes it possible for misfolded hyperphosphorylated tau protein to infiltrate into terminal branches of the axon and into presynaptic terminals. Once there, tau can be transported across the synaptic cleft, causing connected neurons, via their synapses, to become susceptible to AD pathology. These last events, if proven, could support considering AD a "prion-like" disease, where misfolded proteins spread from one cell to another and trigger pathogenic mechanisms in otherwise healthy neurons ([@B79]). Numerous studies have shown prion-like self-propagation of aggregated human tau fibrils, both synthetically prepared and those derived from human AD brain ([@B31]; [@B4]).

Apolipoprotein E and the Inflammatory Hypothesis {#S3.SS2}
------------------------------------------------

In AD pathology, the progression of AD involves not only neurons but also astrocytes and microglia. These cell types in the brain express apolipoprotein E (ApoE), a protein encoded by a gene that is the strongest genetic risk factor for AD ([@B33]; [@B154]). Several studies in the last two decades, including clinical, pathological, epidemiological genome-wide association, and whole-genome sequencing studies, have confirmed the strength of the association between ApoE and AD ([@B148]; [@B86]). Apolipoprotein E predominantly functions as a lipid-binding protein in lipoprotein particles, and it participates in transport and delivery of lipids to target sites ([Figure 2](#F2){ref-type="fig"}). In AD, it seems to be present in Aβ plaques ([@B119]). Interestingly, the *APOE* gene has three common alleles encoding three protein isoforms: ApoE2, ApoE3, and ApoE4. During the preclinical phase of AD, carriers of the ApoE4 allele increase cerebral amyloid deposition at an earlier age and do so faster than non-carriers ([@B60]; [@B113]; [@B143]; [@B21]). Apolipoprotein E seems to exert its effects on neurodegeneration independently from Aβ plaques by modulating tau pathology. Apolipoprotein E4 might make neurons more sensitive to neurodegeneration in the tauopathy mouse model (tauP301S), while its absence may be protective ([@B148]). Moreover, lack of ApoE greatly reduced activation of microglia and astrocytes in this model ([@B148]). Whether ApoE could be defined as a possible missing link between amyloid deposition, tau pathology, and neuroinflammation is not known.

Recently, the amyloid hypothesis has been extended to what can be called the "inflammatory hypothesis," as an increasing number of inflammatory mechanisms have been implicated in AD pathogenesis ([@B82]; [@B98]). Reactive astrogliosis and microgliosis are important pathological features of AD. Microglia play apparently paradoxical roles: protective during amyloid deposition but damaging during tau accumulation. Microglia help clear Aβ during the early stage of AD, but during progression their continued release of proinflammatory cytokines and associated neurotoxins is thought to cause neurodegeneration, which in turn activates more microglia, triggering a vicious cycle. Interestingly, removing microglia during the period of plaque deposition seems to have a protective effect ([@B152]), thus confirming that activated microglia could be involved in some of the changes in the brains of AD patients. Activated microglia also augment the negative effects of tau accumulation ([@B95]).

The Infectious Hypothesis {#S3.SS3}
-------------------------

The so-called infectious hypothesis, first proposed in 1991 ([@B74]), has recently received renewed attention. It was first reported as a correlation of herpesvirus in the brains of AD patients and in amyloid plaques. The infectious hypothesis gained popularity recently when specific viral DNA, belonging to viruses of the family Herpesviridae, was found in three independent cohorts of AD patients, and its presence was then linked via multiscale network analysis to aging and AD development ([@B135]). The proposed pathophysiology supports the idea that abnormal processing of APP to Aβ is aided by the presence of several types of herpes simplex virus (HSV-1, HSV-6, and HSV-7) in the brain, leading to toxic Aβ aggregation and the hyperphosphorylation of tau ([@B71]). Several other microorganisms (ranging from viruses to bacteria) have been linked to AD or, rather, to the hypothetical antimicrobial function of Aβ, which seems to have characteristics similar to antimicrobial peptides ([@B151]). In this view, Aβ fibrillization is a defensive mechanism that triggers the amyloid cascade ([@B109]).

The infectious hypothesis could also partially explain and/or integrate with the role of neuroinflammation as a protective response toward microbial challenge, thus releasing the antimicrobial peptide Aβ, rather than as a consequence of Aβ deposition, as viewed by the amyloid cascade hypothesis.

Olfaction and Alzheimer's Disease {#S4}
=================================

Olfactory impairments, centrally and peripherally, often appear in the early phase of AD, before cognitive impairment is apparent in patients ([@B116]). In these cases, the olfactory system shows the classical signs of AD: intracellular NFTs and Aβ plaques. Amyloid-β peptides, generated from APP, aggregate into extracellular plaques, whereas NFTs result from intracellular accumulation of hyperphosphorylated tau proteins ([@B22]; [@B7]; [@B52]). In postmortem tissues from AD patients, both Aβ plaques and NFTs are found in both OE and OB ([@B160]). Amyloid-β and tau expression can also be found in cells swabbed from the nasal cavity of healthy human subjects ([@B19]).

The Olfactory Epithelium in Alzheimer's Disease {#S4.SS1}
-----------------------------------------------

Several studies in animal models have investigated how the different pathways involved in AD may affect the function of the OE, possibly contributing to olfactory impairment as observed in AD patients.

In a transgenic mouse model that selectively overexpresses the mutated humanized APP (hAPP, with the so-called Swedish and Indiana mutations that facilitate Aβ generation) in either mature or immature ORNs, mature ORNs are more susceptible to stress induced by APP accumulation ([@B28]). Intracellular hAPP accumulation seems to induce neuronal loss, indicating that mechanisms involved in neuronal apoptosis might be cell autonomous ([@B28], [@B29]). The researchers did not observe extracellular plaques when apoptosis of ORNs was evident in the OE and showed that only ORNs expressing hAPP were sensitive to its accumulation. Those not expressing the protein were spared from apoptosis. In wild-type mice, nasal injection of an adenovirus expressing either Bri-Aβ~40~ or Bri-Aβ~42~ fusion proteins, which are cleaved to secrete the human Aβ~40~ or Aβ~42~ peptide, respectively, did not increase apoptotic cells in the OE but, rather, disrupted correct axonal targeting to the OB, without any clear visible sign of plaque deposition ([@B24]).

On the other hand, cell death in the OE seems not to be exclusively cell autonomous. The Tg2576 mouse model expressing hAPP with naturally occurring Swedish mutations (K670N, M671L, hAPPsw), which increases Aβ production by γ-secretase, shows an unusually high accumulation of Aβ~56~, a neurotoxic form of Aβ ([@B81]). Amyloid-β~56~ is a dodecamer of Aβ that, when accumulated in the cortex, seems to be related to cognitive impairments ([@B13]). Interestingly, Aβ~56~ accumulates in the OE before mice show cognitive deficits ([@B81]). The researchers speculated that the increase of the neurotoxic Aβ~56~ could be explained by an upregulation of PSEN1 and PSEN2 only in the OE ([@B81]). Thus, it is possible that APP-processing machinery in the OE differs from that in other regions of the brain.

A later study by the same group showed that the rate of apoptosis in the OE in Tg2576 mice seems to be region specific ([@B168]), indicating that it is possible to dissect out the early signs of AD in defined zones of the OE. The rate of apoptosis also correlated with Aβ accumulation, which was higher in regions with more apoptotic ORNs. This suggests that susceptibility to Aβ accumulation even within the OE might be differently regulated. It is interesting to note that ORs are expressed in specific zones ([@B140]) and that the dorsal OE region displays slowed ORN turnover ([@B162]), suggesting that the region-specific effects of AD might be another sign of heterogeneity of the OE, or potentially linked to mechanisms that drive the aforementioned OE variations. However, transgenic mice overexpressing APP, with a single or multiple amyloidogenic mutant human genes, have mutations not present in the human sporadic form of AD, and the temporal progression of the disease in mice does not correlate well with AD in humans ([@B103]). Thus, these results should be interpreted with caution.

In AD patients, OE supporting cells seem to undergo the same modification and decrease in number as ORNs ([@B18]). Moreover, it has been shown in mice that, after adenoviral infections with either Aβ~40~ or Aβ~42~, the sustentacular cells clearly contain these protein fragments, perhaps indicating their potential role in the uptake and phagocytosis of Aβ ([@B24]), similar to the role played in the brain by microglia, astrocytes, and macrophages ([@B142]).

An aspect that seems peculiar to the olfactory system is that Aβ burden correlates with olfactory impairment ([@B166]); Aβ plaque accumulation, in contrast, does not correlate with the progression of cognitive impairment ([@B145]; [@B98]; [@B116]), although NFT accumulation does correlate with behavior impairments ([@B116]). Because no tau mutations have been found in sporadic AD, mouse models for tau are mainly considered models for dementia ([@B75]), and tau expression might not recapitulate the evolution of NFTs spreading between synaptically connected regions ([@B55]; [@B75]). A transgenic mouse overexpressing tau protein showed behavioral olfactory deficits and intense tau immunoreactivity in the OB ([@B99]).

In postmortem tissues of patients with and without AD, multiple tau protein domains in NFTs have been described in the OE, in what look like ORN axons ([@B94]). More recent studies found higher levels of hyperphosphorylated tau in the OE of AD subjects than in those suffering from other neurodegenerative diseases, and its expression with a morphological appearance typical of NFTs is localized to ORN cell bodies ([@B5]). Deficits in olfactory behavior were demonstrated in the 3xTg-AD mouse model for human AD, which expresses mutations in PSEN1, APP with the Swedish mutations, and mutated tau, leading to development of Aβ and tau pathologic lesions in a sequential manner ([@B123]; [@B25]). However, it is not clear whether Aβ or tau accumulation is responsible for the altered behavior or whether they accumulate in the OE ([@B25]).

An ApoE genotype seems to manifest itself uniquely and early in human ApoE4 carriers with the appearance of olfactory dysfunction ([@B131]; [@B9]; [@B108]; [@B117]; [@B58]; [@B57]; [@B126]), impaired odor identification ([@B117]; [@B124]), and altered olfactory-related evoked potentials ([@B85]; [@B112]). This occurs before other forms of cognitive impairment, for example, impairment associated with Aβ and tau pathology. Previous studies have shown ApoE expression in the sustentacular cells ([@B121]). As a consequence of ApoE deletion in mice, OE recovery from an injury is slowed down ([@B120]). This suggests involvement of sustentacular cell ApoE in regulating ORN maturation and survival under physiologically stressful conditions. Apolipoprotein E from sustentacular cells and ensheathing glia could play important roles in recycling membrane components liberated from senescing ORNs to support cell division and differentiation of basal cells and axonal outgrowth of maturing ORNs. Apolipoprotein E in sustentacular cells may facilitate the traditional supporting role attributed to these cells in OE and to glial cells in the brain ([@B56]; [@B133]; [@B10]).

Odorant Receptors in Alzheimer's Disease {#S4.SS2}
----------------------------------------

A growing number of reports describe ORs expressed in tissues other than the OE ([@B104]). Those ORs have traditionally been called ectopic ORs, or "ecto-nomotopic," to highlight the possibility that the normal function of ORs might not be limited to olfactory perception ([@B41]). Often, ectopic ORs are expressed with other elements of the canonical olfactory signal transduction machinery, such as olfactory G protein G~olf~, AC3, and receptor-transporting proteins. Since the very first description of an OR outside the nose \[in testis; ([@B153])\], several reports have shown OR expression in rodent and human non-chemosensory tissues and organs, such as lung ([@B78]), skin ([@B54]), kidney ([@B130]; [@B147]), pancreas ([@B115]), brain ([@B125]; [@B49]; [@B61]), and a variety of other locations (reviewed in [@B104]). However, few well-described physiological functions have been identified for ectopic ORs ([@B130]; [@B147]; [@B12]). Their possible implications in pathophysiological processes are also elusive. In postmortem tissues of subjects without signs of neurodegenerative diseases, several ORs have been found to be expressed in frontal cortex, entorhinal cortex, and cerebellum. For example, human OR51E1 is one of the few ORs whose expression outside the nose seems higher than in the OE ([@B49]), and along with other ORs, it seems to be expressed also in the brain (see [@B3]). Some ORs were found to be differentially regulated at different stages of AD and in the different brain regions ([@B3]). In addition, a progressive increase in Olfr110 mRNA expression and decreased expression of AC3 in the brain were found at different ages in the hAPPsw/PSEN1 mouse, another mouse model of AD ([@B3]). Interestingly, during AD progression, a stage-dependent regulation of ORs seems to exist in the OB. Recent data of postmortem human OBs showed a transcriptomic fingerprint related to the different stages of AD progression: among the involved genes were OR2T2 and OR5M1, downregulated at intermediate stages, and OR2T8 and OR6J1 genes upregulated in advanced stages ([@B90]). Worth noticing is also the presence of ORs in the OB in a still unknown cell type. Transcriptomic analysis may be worth extending to the OE where data about changes in OR expression profile during AD progression are not available yet.

Together with Olfr110, other ORs have been described in the brain of wild-type mice: Olfr110/111 and Olfr544 proteins are mainly expressed in cortical and hippocampal neurons and at lower levels by astrocytes, microglia, oligodendrocytes, and endothelial cells ([@B53]). The expression of these ORs was evaluated in the 5xFAD transgenic mouse model for AD. These mice exhibited upregulated expression of Olfr110/111 in cortex and hippocampus, and Olfr544 was overexpressed only at 9 months of age in cortex ([@B53]).

A different set of experiments with a different animal model (knock-in for the different human ApoE isoforms), surprisingly, showed that Olfr110 is regulated differently by the different ApoE forms during induced microglia activation ([@B148]). Cultured microglia treated with lipopolysaccharide showed upregulation of proinflammatory genes, including *Olfr110* ([@B148]), which may suggest a potential proinflammatory chemosensing role for this OR, which is poorly expressed in the nose and is enriched in other brain areas ([@B53]). The possibility that ORs may function outside the OE is intriguing because it opens an array of new questions about physiological roles of ORs and their potential roles in AD.

Electrophysiological Responses of the OE in Alzheimer's Disease {#S4.SS3}
---------------------------------------------------------------

Few studies have addressed the electrophysiological properties of ORNs or of the entire epithelium in AD. The OE in humans is accessible for electrophysiological recordings, and its response to odorants can be measured ([@B92]; [@B91]). Human ORNs are also accessible for biopsy and subsequent functional investigation ([@B134]).

ApoE-knockout (KO) mice display a deficit in odorant responses recorded from the OE surface via electro-olfactograms ([@B171]), which represent the summed generator potential recorded from multiple ORNs in the OE that are activated by an odorant. Hence, electro-olfactograms depend on the number of responsive ORNs in the OE and could also reflect the change of function of transduction proteins ([@B129]; [@B150]; [@B37]; [@B36]). Apolipoprotein E--KO mice showed both a deficit in the amplitude of odorant responses and a lack of adaptation at ages 3--5 months ([@B171]). To our knowledge, no further electrophysiological data are available of mouse models for AD.

It would be interesting to know more about what changes occur when ORNs begin to accumulate proteins that trigger apoptotic events in AD. Changes in intrinsic neural activity, including hyperactive and hypoactive neural systems, in mouse models of AD have been reported for a number of different types of neurons, including early-life hyperactivity in the OB that may result from Aβ and other APP metabolites ([@B165]; [@B141]). Some ORNs are characterized by higher spontaneous activity, determined by the OR type they express ([@B136]; [@B32]). This spontaneous activity dictates the physiology of these ORNs ([@B43]) and their targeting to the OB ([@B70]; [@B118]; [@B159]). The role of BACE1 (β-site amyloid precursor protein cleaving enzyme 1) in glomerular targeting is zone specific ([@B168]) or OR dependent ([@B132]; [@B23]). It is tempting to speculate that the different phenotypes may be dependent on the spontaneous activity of the ORs and the ORNs.

Mitochondrial dysfunction has received increased attention as one of the main mechanisms that can cause sporadic late-onset AD ([@B26]). Mitochondria in the dendritic knob contribute directly to Ca^2+^ homeostasis and are responsible for Ca^2+^ clearance during odorant stimulation. It is noteworthy that pharmacologically altering the inner mitochondrial membrane potential leads to a shift of the dynamic range of the ORN stimulus--response function and detrimentally affects odorant responses ([@B50]). Thus, early events during AD that may involve mitochondria could alter olfactory transduction and could be detected by measuring ORN activity ([@B50]).

Olfactory System Neuroregeneration in Alzheimer's Disease {#S4.SS4}
---------------------------------------------------------

As the peripheral olfactory system regenerates throughout life, this imposes additional challenges during the progression of AD both for newly born ORNs and the integration of their axons in the bulbar circuitry.

The OE basal cells are responsible for the replacement of all OE cell types throughout the life span ([@B59]; [@B146]). As basal cells differentiate into mature ORNs, they pass through a stage as immature ORNs, characterized by the expression of GAP43, which has been extensively used as a marker for this cell population. In a transgenic mouse model, overexpressing mutated hAPP in either immature or mature ORNs was sufficient to induce neuronal cell death ([@B28]). One difference, though, was that the rate of immature cell production was increased. Interestingly, this animal model allowed temporal control of hAPP expression, and after a period of hAPP production, the researchers shut off its expression and found that immature neurons were less susceptible than mature ORNs to apoptosis. Also, immature ORNs recovered from neurodegeneration faster than mature ORNs ([@B28]). This study is the only reported exploitation of OE stem cells in AD research. Note that in both mice and humans the OE tends to lose its neuroregenerative ability with age ([@B30]): GBCs somehow run out, HBCs alone are no longer sufficient, and the OE becomes non-neurogenic ([@B146]).

Neuroregeneration also occurs in the OB. The synapses of ORNs are subject to renewal as, for example, PGCs are continuously integrated into the glomerular circuit even in adult mice ([@B96]), although PGCs represent only ∼5% of the total number of newborn neurons in the OB ([@B11]; [@B96]). Different specialized precursor populations in the subventricular zone (SVZ) are thought to generate the different PGCs ([@B107]). Following sensory deprivation, survival of new PGC declines ([@B101]), whereas survival of adult-generated PGCs can be increased by olfactory enrichment and learning ([@B1]; [@B96]).

Granule cells are GABAergic, axonless interneurons, releasing GABA across a reciprocal dendrodendritic synapse with mitral and tufted cells. During adulthood, newborn GCs in many mammalian species migrate from the SVZ of the anterior forebrain to the OB where they integrate into the OB circuitry, where the maturation of the immature GCs is uniquely influenced by sensory and top-down activity (reviewed in [@B96]).

In the hAPPsw/PSEN1 mouse model, where both hAPPsw and mutated PSEN1 are present, Aβ deposition is restricted to the GC layer ([@B144]). Granule cells are a subpopulation of somatostatin-expressing neurons that decrease with age, or abruptly in hAPPsw/PSEN1 mice ([@B39]). Transgenic mice that express single mutant variants of APP or PSEN1 showed several different neurogenic phenotypes ([@B93]) during the progression of AD symptoms. Neurogenesis either increased or decreased in response to neurodegenerative processes ([@B27]; [@B144]). Different results regarding the rate of neurogenesis may depend on amyloid plaque deposition in the SVZ, which appears to be toxic to progenitor cells. This suggests that survival of progenitor cells in the SVZ is reduced in AD, and the net result is decreased SVZ proliferation ([@B34]).

The Olfactory Bulb in Alzheimer's Disease {#S4.SS5}
-----------------------------------------

In adult rats, APP protein is highly expressed in the OB, olfactory nerve layer, external plexiform layer, and glomerular layer, and damage to the OE increases expression of APP in the OB ([@B156]). In humans, Aβ deposition occurs in the OB prior to the appearance of cognitive symptoms ([@B7]). In the Tg2576 mouse model, which overexpresses hAPPsw, non-fibrillary Aβ deposition has been observed earlier in the OB than in other brain areas ([@B166]). Furthermore, axonal targeting of ORN axons to glomeruli in the OB is disrupted in mice bearing the hAPPsw mutation ([@B24]).

The effects of overexpressing hAPPsw have been investigated in an OR-dependent manner by crossing mice that express hAPPsw only in mature ORNs with mouse lines that express the GFP or LacZ reporter in ORNs expressing the *P2*, *MOR28*, and *M71* OR genes. These mice showed that axonal projections terminate within multiple glomeruli per half bulb ([@B24]) instead of in a single glomerulus. The ORN-specific restricted expression of hAPPsw and the bulbar mistargeting allowed the researchers to determine how these connectivity deficits altered odorant-driven behaviors. They found that mice with the amylogenic mutations needed increased time to find a hidden food source and spent more time close to where a repulsive fox-urine--derived compound had been deposited, suggesting that these mice had reduced olfactory abilities.

In addition, the researchers tested for odorant responses in the OB of hAPPsw mice by monitoring tyrosine hydroxylase (TH) expression as a proxy for ORN-driven input activity, using immunofluorescence. They showed that periglomerular dopaminergic neurons had reduced TH expression. They also tested for reduced expression of the immediate--early gene *Arc* in periglomerular and tufted neurons ([@B24]). Because periglomerular and tufted neurons in the OB do not express hAPPsw themselves, these reduced levels of TH and *Arc* are thought to be caused by reduced input from ORNs ([@B24]). It is noteworthy that the more neurotoxic Aβ~56~ form seems to be present in the early phase of AD in adult Tg2576 mouse ORNs (see *The Olfactory Epithelium in Alzheimer's Disease* and [@B168]), and the decreased ORN activity may be due to its accumulation.

An interesting aspect of the work by [@B24] is the use of mice with ORN-specific overexpression of either hAPPwt (a non--Aβ-forming form of human APP) or hAPPmv (which does not allow BACE1 to cleave APP), which did not reveal any connectivity defects. This reinforces the idea that expression of hAPPsw produces Aβ as a product of APP cleavage by BACE1 in mice *in vivo* and alters the neuronal circuitry of the peripheral olfactory system in the absence of plaques. The mistargeting phenotype is observed without any plaques in both young and adult mice. Indeed, the same phenotype can be found in adult wild-type mice by virally expressing Aβ~40~ or Aβ~42~ in the OE. Together, these data are consistent with soluble Aβ triggering axonal dysfunction and mistargeting in the absence of amyloid plaques *in vivo* ([@B24]).

The appearance of a specific AD phenotype in the absence of plaques has also been shown recently in the OB by proteomics and analysis of mice expressing hAPPsw protein ([@B88]). Using these methods, the researchers were able to differentiate variations in protein and transcript levels that were peculiar in the various stages of AD progression (i.e., early vs late stage of AD) ([@B88]). When APP is overexpressed, AD stage-related regulatory effects on kinase dynamics (SEK1/SAPK, PKA) could be detected in the OB. Interestingly, these same kinases are differentially affected in OB samples from patients at different stages of AD progression ([@B89], [@B88]).

BACE1 is necessary to generate Aβ peptide, but in the olfactory system, it seems to play a role in glomerular targeting in the OB. The precise targeting of ORN axons is disturbed in BACE1-KO mice ([@B132]; [@B23]). BACE1 protein localizes mainly to the proximal segment and the terminus of ORN axons, and the expression of BACE1 correlates inversely with odor-evoked neural activity. Crossing BACE1-KO mice with mice whose ORs have been tagged with a GFP or LacZ reporter ([@B132]; [@B23]) showed OR-specific mistargeting and multiple ectopic glomeruli: MOR28 targeted correctly, but P2 and M71 did not. These three ORs project to different regions of the OB, indicating that the role of BACE1 in the precision of axonal targeting depends on the specific region of the OB ([@B23]). The deletion of BACE1 also seemed to reduce TH levels in the OB compared to wild-type controls, again indicating reduced ORN input to the glomeruli.

This reduction in the input does not depend on neuronal loss in the OE, because in BACE1-KO mice the number of ORNs in the OE seems to be unaltered ([@B23]). Intriguing is the idea that BACE1 has several other substrates besides APP (e.g., ephrin-A5 and protocadherins) that are cell-surface molecules with defined roles in axon guidance of mouse ORN axons ([@B35]; [@B63]; [@B23]). Whether BACE1 activity in the olfactory system is somehow connected to the fact that the olfactory system is extremely sensitive to AD progression is not clear yet, but it calls for careful evaluation when using an AD drug that targets BACE1 ([@B132]).

The observed axonal pathology might depend on the level of expression of BACE1 such that, when recruited for APP cleavage in animal models of AD, BACE1 no longer functions properly as a guidance/targeting receptor. Indeed, it has been suggested that changes in the expression pattern of proteins involved in homeostasis, within brain regions that express more of the proteins involved in APP processing, might make those regions more vulnerable to AD development ([@B51]). This could be the case of the olfactory system and its components ([@B141]). Apolipoprotein E is especially enriched in the primary olfactory pathway ([@B100]; [@B121]). In the OB, ApoE is expressed by glial cells around the glomeruli ([@B155]). Despite its expression in glial cells, ApoE is involved in controlling odor sensing and processing in mice ([@B171]). In ApoE-KO animals, the entire OB circuitry is altered, indicating that ApoE may be responsible for the correct balance between excitatory and inhibitory inputs, which are altered in the OB of ApoE-KO mice because of reduced ORN signaling to the OB circuitry ([@B171]). Altered OB circuitry, together with impaired olfactory-driven behavior, is also present in a mouse model carrying the humanized ApoE4 mutation ([@B48]).

Conclusion and Future Perspectives {#S5}
==================================

The sense of smell is impaired in patients suffering from AD and in individuals at risk of AD. This review has focused on AD pathophysiology relating to events taking place in the olfactory system at the early processing stages, in particular, the OE and OB in mouse models of AD ([Figure 3](#F3){ref-type="fig"}). Similar to humans, mice show early AD pathophysiological symptoms in olfactory areas, both peripherally and centrally. Changes occurring in the OE that lead to neurodegeneration seem to be cell autonomous and independent of plaque accumulation.

![Working models of olfactory deficit arising in the olfactory epithelium in mouse models of Alzheimer's disease. Top, Overexpression of mutated human amyloid precursor protein (hAPP) induces an upregulation of γ-secretase complex, leading to the production of different types of Aβ peptides ([@B28], [@B29]; [@B81]). Amyloid-β 40/42 (Aβ~40/42~) causes axonal mistargeting of olfactory receptor neurons (ORNs) in the olfactory bulb (OB) ([@B24]), whereas Aβ~56~ causes ORN apoptosis ([@B81]). Middle, Mutation of tau also causes ORN apoptosis. Bottom, Apolipoprotein E deficiency alters the maturation of ORNs. All these alterations lead to deficits in olfactory-driven behaviors ([@B120]; [@B171]).](fnins-14-00440-g003){#F3}

Odorant responses in the OE are also decreased in several mouse models of AD, recapitulating the decreased olfactory ability observed in humans. In the OB, changes in AD pathophysiology involve mechanisms of glomerular map formation, altered circuitry, and neuroregeneration. The latter offers an interesting angle on future research to understand if olfactory regeneration can slow down or make the system more susceptible to olfactory decline. Tying in with this point, few studies have addressed the susceptibility of stem cells to AD-driven degeneration or why they no longer replace dying ORNs, which may warrant future studies, including how stem cells "burn out" in the elderly population at higher risk of AD and how well aging stem cells keep pace with neurodegeneration in AD mouse models. In particular, it would be important to understand how different mutations in AD mouse models drive different or similar olfactory AD symptoms. Interestingly, in addition to cells in the olfactory system, cells that express ORs outside the nose are differentially regulated in AD. Therefore, ORs, as GPCRs, could be a valid target for AD drug development, if their role in the brain, outside olfactory areas, and their differential regulation are confirmed and further understood.

The olfactory system seems highly vulnerable to AD, especially in its early stages. The OE may be a prime target to investigate hitherto elusive pathophysiological mechanisms that lead to AD. In this review, we have highlighted how this and other aspects of the olfactory system offer suitable models to address several unsolved mysteries of AD.
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A β

:   amyloid- β

AC3

:   adenylyl cyclase type 3

AD

:   Alzheimer's disease

ApoE

:   apolipoprotein E

APP

:   amyloid precursor protein

BACE1

:   β-site amyloid precursor protein cleaving enzyme 1

GBCs

:   globose basal cells

GCs

:   granule cells

GPCRs

:   G protein--coupled receptors

hAPP

:   humanized APP

hAPPsw

:   naturally occurring Swedish human APP mutation

HBCs

:   horizontal or dark basal cells

KO

:   knockout

NFTs

:   neurofibrillary tangles

OB

:   olfactory bulb

OE

:   olfactory epithelium

OMP

:   olfactory marker protein

ORNs

:   olfactory receptor neurons

ORs

:   odorant receptors

PD

:   Parkinson's disease

PGCs

:   periglomerular cells

PSEN1, PSEN2

:   secretase enzymes

SVZ

:   subventricular zone

TH

:   tyrosine hydroxylase.
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